INHIBRX BIOSCIENCES, INC. Other Receivables, Net, Current
INHIBRX BIOSCIENCES, INC. (INBX) had Other Receivables, Net, Current of $132.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:OtherReceivablesNetCurrent · last filed 2026-08-13
- 2026-06-30: Other Receivables, Net, Current $132.00K.
- 2026-03-31: Other Receivables, Net, Current $186.00K.
- 2025-12-31: Other Receivables, Net, Current $177.00K.
- 2025-09-30: Other Receivables, Net, Current $727.00K.
| Period end | Other Receivables, Net, Current | Other Receivables, Net, Current as first filed |
|---|---|---|
| 2026-06-30 | $132.00K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $186.00K 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $177.00K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $727.00K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $730.00K 10-Q · filed 2025-08-13 | |
| 2024-12-31 | $197.00K 10-K · filed 2026-03-19 | $41.00K 10-Q · filed 2025-08-13 |
| 2024-06-30 | $952.00K 10-Q · filed 2024-08-13 | |
| 2023-12-31 | $607.00K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |